Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy
Epigenomics Review of the rationale behind the use of an epigenetic therapy as a potential pharmacological treatment of Duchenne muscular dystrophy, by Silvia Consalvi, Valentina Saccone and Chiara Mozzetta, from IRCCS Santa Lucia Foundation and CNR Institute of Cellular Biology & Neurobiology (both Rome, Italy).
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.